Skip to Content
Morningstar

Exact Sciences Corp EXAS

Morningstar Rating
Unlock
Stock XNAS Rating as of
$60.96 −2.52 (3.97%)
View Full Chart
As of Delayed Price Post-Trading: $60.96 0.00
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Exact Sciences' Cancer Screening Foothold Is Strong, but Liquid Biopsy Pipeline Not Derisked Yet

Jay Lee

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype Dx, its tissue-based genomic profiling platform with widespread use in breast cancer. It has a promising pipeline in the nascent liquid biopsy market, including a tissue-informed molecular residual disease, or MRD, test, a blood-based CRC screening test, and a multicancer early detection, or MCED, test.

Read Full Report

Price vs Fair Value

View History
EXAS is trading at a 19% discount.
Price
$63.45
Fair Value
$97.00
Uncertainty
Very High
1-Star Price
$654.50
5-Star Price
$34.00
Economic Moat
Tmc
Capital Allocation
Zwcjvyqv

Bulls Say, Bears Say

Bulls

Cologuard’s staying power is underappreciated. It could take years for liquid biopsy to steal share, and Cologuard’s market share could soar past 10%.

Bears

Exact has yet to reach profitability, and the market is giving the company credit for significant future success despite historical lack of profitability.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EXAS is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$63.48
Day Range
$60.37–63.48
52-Week Range
$56.05–100.77
Bid/Ask
$60.00 / $60.96
Market Cap
$11.07 Bil
Volume/Avg
2.2 Mil / 2.5 Mil

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
4.57
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Growth
Total Number of Employees
6,600
Website
https://www.exactsciences.com

Competitors

Valuation

View More
Metric
EXAS
MYGN
GH
Price/Earnings (Normalized)
 ———
Price/Book Value
 3.662.1212.78
Price/Sales
 4.572.033.31
Price/Cash Flow
 73.09——
Price/Earnings
EXAS
MYGN
GH

Financial Strength

Metric
EXAS
MYGN
GH
Quick Ratio
 1.911.646.11
Current Ratio
 2.322.016.54
Interest Coverage
 −7.26−90.28−198.43
Quick Ratio
EXAS
MYGN
GH

Profitability

Metric
EXAS
MYGN
GH
Return on Assets (Normalized)
 −0.51%−1.93%−20.62%
Return on Equity (Normalized)
 −1.05%−2.88%−253.35%
Return on Invested Capital (Normalized)
 −0.23%−2.33%−25.20%
Return on Assets
EXAS
MYGN
GH
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Diagnostics & Research Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
TMO
Thermo Fisher Scientific IncWbygqwpmwWft$206.7 Bil
DHR
Danaher CorpZgdwzkzbrNmlldt$175.0 Bil
IQV
IQVIA Holdings IncHfbwsszhCxvxfj$41.3 Bil
IDXX
IDEXX Laboratories IncRmfvysvkZnczbjd$39.7 Bil
A
Agilent Technologies IncVqsljtnqhJhxvv$38.8 Bil
MTD
Mettler-Toledo International IncTsxwhzrvyGtwcc$25.5 Bil
ICLR
Icon PLCZkzjyjwXbfyvy$24.1 Bil
ILMN
Illumina IncSfdfpzmxQcrxg$18.6 Bil
WAT
Waters CorpNrbfmrmfwbXqsm$18.0 Bil
LH
Laboratory Corp of America HoldingsHtpknzswdCzjkyqg$16.8 Bil

Sponsor Center